Mesoblast Med Cuts Mortality in Patients Under 65 Years With Moderate/Severe COVID-19 ARDS

 

• Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old

• In these patients the benefit was further increased when remestemcel-L was used with dexamethasone as part of standard of care

• Mortality reduction by remestemcel-L was accompanied by increased days alive off mechanical ventilation and reduced days in hospital

• Plan to meet with U.S. Food and Drug Administration (FDA) to discuss potential next steps

https://finance.yahoo.com/news/remestemcel-l-reduces-mortality-patients-233200681.html